Skip to content
value.today

Electra Therapeutics, Inc.

Total raised
$134 M
1 round on record
Latest round
$134 M
Oct 2025
First round on record
Oct 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Electra Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$134 MNo. 1$50 to $250 million

Electra Therapeutics, Inc.: Raise no. 1, Oct 2025

Investors in this round

19 investors had bought by the notice of Oct 30, 2025: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Electra Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$134 M of $184 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Quehuong (Kathy) Dong, Pharm.D. · Executive Officer, Director
  • Beth Seidenberg, M.D. · Director
  • Carl Gordon, Ph.D. · Director
  • Matthew Fust · Director
  • Nancy Stagliano, Ph.D. · Director
  • Thomas Geninatti, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Quehuong (Kathy) Dong, Pharm.D., President and CEO. Source: SEC Form D, newest notice filed Oct 30, 2025. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Electra Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).

    SEC Form D · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

That is all the official record says: Electra Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Electra Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Gary S. KoePersonnot statednot statedHeld Series A preferred stock (Form 3, 2026)SEC Form 3
Graham ParryPersonnot statednot statedHeld Series A preferred stock (Form 3, 2026)SEC Form 3
Nancy StaglianoPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2026)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2026)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2026)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2026)SEC Form 3
Quehuong (Kathy) DongPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Electra Therapeutics, Inc.
NameRoleNamed in
Quehuong (Kathy) Dong, Pharm.D.Executive officerOct 2025
Beth Seidenberg, M.D.DirectorOct 2025
Carl Gordon, Ph.D.DirectorOct 2025
Matthew FustDirectorOct 2025
Nancy Stagliano, Ph.D.DirectorOct 2025
Quehuong (Kathy) Dong, Pharm.D.DirectorOct 2025
Thomas Geninatti, Ph.D.DirectorOct 2025